CD8A and rheumatoid arthritis: Collectively, these researches suggest that administration of IL-22 and other strategy, including type II collagen-driven anterior chamber-associated immune deviation (ACAID)-mediated immune tolerance via the generation of CD8+ Tregs, treated with GM-CSF or OX40L, could have therapeutic potential in context of RA[51, 58–60].